Liver Cancer
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC (UW09018)
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Emboliztion (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study
Investigator: Edward Lin, MD; Conditions: Liver Cancer; Status: Recruiting; Study ID: NCT00908752
A Randomized Phase III, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Everolimus (RAD001) in Adult Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment - The EVOLVE-1 Study
Investigator: Samuel Whiting, MD, PhD; Conditions: Hepatocellular Carcinoma (Liver Cancer); Status: Recruiting; Study ID: NCT01035229
Join Us On